Literature DB >> 4635505

Respiratory diseases in cyclophosphamide-treated mice. II. Decreased virulence of PR8 influenza virus.

S H Singer, P Noguchi, R L Kirschstein.   

Abstract

Mice infected intranasally with the PR8 strain of influenza virus were treated with cyclophosphamide, a potent immunologic suppressor. During the first week of infection, mortality in the unmodified influenza infection averaged 65%, whereas in those animals also treated with cyclophosphamide it averaged 22.5%. After the first week, the mortality rate in the infected cyclophosphamide-treated animals rose to that seen during the first week in the animals only infected. This decreased mortality in the first week was found despite the fact that the cyclophosphamide-treated and infected animals had higher virus titers which persisted longer, decreased circulating antibody, and a decreased interferon response. This delayed mortality appeared to be related to the finding of decreased cellular infiltration in the lungs of infected cyclophosphamide-treated animals.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4635505      PMCID: PMC422471          DOI: 10.1128/iai.5.6.957-960.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Role of interferon in recovery from virus infections.

Authors:  A ISAACS; G HITCHCOCK
Journal:  Lancet       Date:  1960-07-09       Impact factor: 79.321

2.  Suppression of influenza viral pneumonia in mice by the non-specific action of xerosin.

Authors:  H S GINSBERG
Journal:  J Immunol       Date:  1955-12       Impact factor: 5.422

3.  Suppression of viral pneumonia in mice by a microbial product (APM).

Authors:  V GROUPE; L H PUGH; A S LEVINE
Journal:  Proc Soc Exp Biol Med       Date:  1952 Aug-Sep

4.  Some factors affecting the interferon-induced antiviral state.

Authors:  S Baron; C E Buckler; H B Levy; R M Friedman
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

5.  Factors modifying host resistance to viral infection. I. Effect of immunosuppressive drugs on experimental infection of mice with encephalomyocarditis virus.

Authors:  B R Murphy; L A Glasgow
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

6.  Role of serum protective factor (SPF) in Langat virus infection of neonatally thymectomized, cyclophosphamide-treated, or antilymphocyte-treated mice.

Authors:  I S Thind; W H Price
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

7.  Potentiation of experimental arbovirus encephalitis by immunosuppressive doses of cyclophosphamide.

Authors:  G A Cole; N Nathanson
Journal:  Nature       Date:  1968-10-26       Impact factor: 49.962

8.  Effectiveness of an interferon stimulator in immunosuppressed mice.

Authors:  M Worthington; S Baron
Journal:  Proc Soc Exp Biol Med       Date:  1971-02

9.  Cyclophosphamide-induced tolerance to equine globulin and to equine-anti-mouse-thymocyte globulin in adult mice. I. Studies on antigen and drug requirements.

Authors:  G D Stockman; J J Trentin
Journal:  J Immunol       Date:  1972-01       Impact factor: 5.422

10.  Respiratory diseases in cyclophosphamide-treated mice. I. Increased virulence of Mycoplasma pulmonis.

Authors:  S H Singer; M Ford; R L Kirschstein
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  20 in total

1.  Effect of cyclophosphamide on infections in mice caused by virulent and avirulent strains of influenza virus.

Authors:  J Hurd; R B Heath
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Studies on the immune response and pathogenesis of Sendai virus infection of mice. III. The effects of cyclophosphamide.

Authors:  G Blandford
Journal:  Immunology       Date:  1975-05       Impact factor: 7.397

3.  Effect of immunosuppression on the genetic resistance of A2G mice to neurovirulent influenza virus.

Authors:  R A Fiske; P A Klein
Journal:  Infect Immun       Date:  1975-03       Impact factor: 3.441

4.  The role of humoral immunity in host defence against influenza A infection in mice.

Authors:  J L Virelizier; J S Oxford; G C Schild
Journal:  Postgrad Med J       Date:  1976-06       Impact factor: 2.401

5.  Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.

Authors:  Mitsutaka Kitano; Makoto Kodama; Yasushi Itoh; Takushi Kanazu; Masanori Kobayashi; Ryu Yoshida; Akihiko Sato
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

6.  Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK.

Authors:  S Tsuru; K Nomoto; M Taniguchi; H Fujisawa; Y Zinnaka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Effects of low- and high-passage influenza virus infection in normal and nude mice.

Authors:  P R Wyde; R B Couch; B F Mackler; T R Cate; B M Levy
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

8.  Effect of anti-mu-chain-specific immunosuppression on Chikungunya virus encephalitis of mice.

Authors:  M Giovarelli; I Viano; M Zucca; R Valbonesi; F Dianzani
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infection.

Authors:  John A Rutigliano; Peter C Doherty; John Franks; Melissa Y Morris; Cory Reynolds; Paul G Thomas
Journal:  J Immunol Methods       Date:  2008-04-28       Impact factor: 2.303

10.  Pharmacological modulation of suppressor cell activity in mice with disseminated histoplasmosis.

Authors:  G S Deepe; G R Kravitz; W E Bullock
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.